Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

149 Bio LLC
Profile last edited on: 3/11/2024      CAGE: 8J9F3      UEI: PUXSSH1GHNF7

Business Identifier: Developing Integrin Activators as First-In-Class Kidney Disease Therapeutics
Year Founded
2020
First Award
2023
Latest Award
2023
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1951 Nw 7th Avenue Suite 600
Miami, FL 33136
   (305) 306-0015
   info@149bio.com
   www.149bio.com
Location: Single
Congr. District: 26
County: Miami-Dade

Public Profile

149 Bio is a startup company developing breakthrough medicines to treat kidney diseases. Firm have developed a novel proprietary platform to identify and develop novel therapeutic candidates. Company's platform allows rapid discovery and determines their mechanism of action to rapid drug development.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$306,500
Phase II Dollars
$0
Total Awarded
$306,500

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
0 1 NIH $306,500
Project Title: Integrin-Targeted Novel Oral Therapeutics for Lupus Nephritis

Key People / Management

  Vineet Gupta -- Founder, CEO

  Santiago Balza -- Research Scientist

  Antonio Barbosa -- Vice President Research

  Darlah Michelle Lopez -- Staff Scientist

Company News

There are no news available.